ELISA News and Research

RSS

SARS-CoV-2 DNA vaccine tested in animal model

A team of experts has tested the immune responses elicited by mucosal homologous plasmid and a heterologous immunization strategy using a plasmid vaccine and a Modified Vaccinia Ankara (MVA) expressing SARS-CoV-2 spike (S) and nucleocapsid (N) antigens.

21 Feb 2021

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

The primary aim of any vaccine is to stimulate immune functions and confer long-lasting protection. A paper recently uploaded to the preprint server bioRxiv by Tong et al. (17th Feb 2021) describes a novel vaccine utilizing PIKA adjuvant and recombinant spike proteins against COVID-19 disease that promises the generation of potent neutralization antibodies, which potentially support immune responses for years.

21 Feb 2021

SARS-CoV-2 D614G mutation associated with lower antibody binding

The onset of the COVID-19 pandemic has brought about an international effort to uncover the biology of its causative agent, SARS-CoV-2, and to develop effective and safe antivirals to contain and treat the infection. A new study by a team of researchers in France and Sweden discusses one such study, exploring the relative immunogenicity of the three main structural proteins of the virus.

18 Feb 2021

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

In the study, published on the preprint server bioRxiv, the team evaluated the ability of AS03, CpG 1018 formulated in Alum, the TLR-7 agonist adsorbed to Alum (AS37), the squalene-in-water emulsion (O/W), and Alum to boost protective immunity against SARS-CoV-2.

15 Feb 2021

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

A new preprint research paper posted to the bioRxiv server demonstrates the potential of using the pre-existing protective responses to produce a broad-spectrum neutralizing response against not just SARS-CoV-2 but other future pathogens.

14 Feb 2021

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Researchers from Cuba, China, and France have demonstrated the potential of coupling a viral antigen with the tetanus toxoid protein as a vaccination approach to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

14 Feb 2021

Could Galectin-3 be a potential biomarker to help identify severe COVID-19 early?

Researchers have measured the galectin-3 levels in the sera of hospitalized patients. They found initial high levels indicate patients will become severely ill, suggesting it could be used as a predictor of severe disease.

10 Feb 2021

Researchers create bone replicas using a hot nano-chisel

A holy grail for orthopedic research is a method for not only creating artificial bone tissue that precisely matches the real thing, but does so in such microscopic detail that it includes tiny structures potentially important for stem cell differentiation, which is key to bone regeneration.

9 Feb 2021

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers in China have developed three SARS-CoV-2 nanoparticle vaccines, containing receptor-binding domain (RBD) trimer, S1 trimer, and ectodomain (ECD) trimer, respectively. To do this, they have used Ferritin nanoparticle self-assembly technology.

9 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

A new preprint research paper released on the bioRxiv server discusses the findings from a model that assesses the association between the immunogenicity and protection conferred by a set of adenovirus- (Ad26)-vectored vaccines that express stabilized SARS-CoV-2 spike protein.

3 Feb 2021

Single-dose vaccination effective for healthcare workers with prior SARS-CoV-2 infection

The findings reveal that healthcare workers previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop significantly higher antibody titers in response to a single dose of COVID-19 vaccine, as compared to healthcare workers without prior SARS-CoV-s infection. The study is currently available on the medRxiv* preprint server.

2 Feb 2021

Previous SARS-CoV-2 infection may negate need for two vaccine doses

Researchers in the United States have shown that two doses of vaccine may not be necessary to protect against coronavirus disease 2019 (COVID-19) among people who have already been infected with the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Feb 2021

Albumin: The Natural Choice for Diagnostic Tests

The availability of established diagnostic kits has enabled researchers to plug-and-play in the design of COVID-19 diagnostics. Such technologies took decades to optimize, but they are now playing an important role in identifying and managing the spread of COVID-19. Recombumin® provides an enhanced solution as part of this toolbox for dealing with this disease

From Albumedix Ltd. 2 Feb 2021

Urinary shedding of spike protein in COVID-19 patients

A team of scientists from the United States has recently revealed that about 25% of people with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection develop renal complications and that the viral spike protein can be detected in the urine samples of these patients. The study is currently available on the medRxiv* preprint server.

1 Feb 2021

By July of 2020, 16.8 million people in the US infected with SARS-CoV-2 and didn’t know it

A seroprevalence study of nearly 10,000 people in the United States in the first six months of the COVID-19 pandemic suggests there were at least five people with undiagnosed disease for every case diagnosed.

1 Feb 2021

CDC examines COVID-19 outbreak among U.S. office workers: a case study in transmission

Researchers from the Centers for Disease Control and Prevention and the Federal Emergency Management Agency in the U.S. found that despite mitigation efforts, two COVID-19 outbreaks emerged among office workers in Washington, DC.

1 Feb 2021

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

Researchers have demonstrated that the prime or prime-boost vaccination of Moderna vaccine in hamsters induced robust neutralizing antibodies, ameliorated weight loss, and suppressed SARS-CoV-2 replication in the airways.

28 Jan 2021

Machine learning identifies patterns of maternal autoantibodies associated with autism

Using machine learning, researchers at the UC Davis MIND Institute have identified several patterns of maternal autoantibodies highly associated with the diagnosis and severity of autism.

26 Jan 2021

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

With the emergence of COVID-19 (coronavirus disease 2019), researchers have been closely investigating the complex interplay between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the human immune system, and COVID-19 disease severity.

25 Jan 2021

ELISA News and Research

SARS-CoV-2 DNA vaccine tested in animal model

Novel SARS-CoV-2 vaccine utilizes recombinant spike protein with PIKA adjuvant

SARS-CoV-2 D614G mutation associated with lower antibody binding

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

Naïve B cells can neutralize SARS-CoV-2 via RBD recognition

Vaccine candidate containing tetanus toxoid potentially protective against SARS-CoV-2

Could Galectin-3 be a potential biomarker to help identify severe COVID-19 early?

Researchers create bone replicas using a hot nano-chisel

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Insight into role of aging in response to SARS-CoV-2 infection

J&J SARS-CoV-2 vaccine shows immunity in non-human primates 6 months after vaccination

Single-dose vaccination effective for healthcare workers with prior SARS-CoV-2 infection

Previous SARS-CoV-2 infection may negate need for two vaccine doses

Albumin: The Natural Choice for Diagnostic Tests

Urinary shedding of spike protein in COVID-19 patients

By July of 2020, 16.8 million people in the US infected with SARS-CoV-2 and didn’t know it

CDC examines COVID-19 outbreak among U.S. office workers: a case study in transmission

Moderna vaccine shows robust suppression of SARS-CoV-2 infection in animal model

Machine learning identifies patterns of maternal autoantibodies associated with autism

Circulating antiphospholipid antibodies drive endothelial cell activation in COVID-19

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News